Increased antiandrogen enzalutamide sensitivity via altering prostate cancer stem cell traits through modulating the androgen receptor-mediated CDR1/circCDR1-AS/miR-1290/BMP4 signaling
Sign Up to like & getrecommendations! Published in 2025 at "Oncogene"
DOI: 10.1038/s41388-025-03482-1
Abstract: While the recent FDA-approved antiandrogen enzalutamide (Enz) might prolong the survival of castration-resistant prostate cancer (CRPC) patients by an additional 4.8 months, most patients eventually might still develop Enz resistance within 6–12 months. Although few… read more here.
Keywords: circcdr1; mir 1290; prostate cancer; cdr1 circcdr1 ... See more keywords